In this funding project, we will test a novel therapy option for acute myeloid leukemia (AML) treatment, in which tumor cell-specific antibodies as transport molecules are used to introduce siRNAs as an efficient therapeutic agent into the AML cells, where they are able to silence malignant modified gene products and thus inhibit leukemia growth. This form of therapy has so far only been carried out on a laboratory scale, for the transfer into clinical practice many further steps are necessary to ensure the necessary quantity, quality and safety, which are funded by the translational research funding line of the EKFS.